A way to revive failed livers through stem cells could be available within the next few years as clinical tests of a new treatment regimen are underway. Pharmicell, a Korean pharmaceutical company developing stem cell therapeutics, said Monday that it has submitted a plan for the commercialization of “Livercellgram,” a stem cell therapy for liver failure, to the Korea Food and Drug Administration (KFDA).
The company said that it successfully completed research trials, which began in 2009, and confirmed that the therapy was effective in curing alcohol induced cirrhosis. The company will begin secondary stage clinical trials if the plan is approved by the KFDA. If the product is approved, Pharmicell will be the first beneficiary of a revised rule made by the KFDA last year which allows research trials to replace a first round of clinical trials.
For full article see Korea Times.